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Abstract: The hypoxic ventilatory response (HVR) at sea level (SL) is moderately predictive of the 
change in pulmonary artery systolic pressure (PASP) to acute normobaric hypoxia. However, because of 
progressive changes in the chemoreflex control of breathing and acid-base balance at high altitude (HA), 
HVR at SL may not predict PASP at HA. We hypothesized that resting peripheral oxyhemoglobin 
saturation (SpO2) at HA would correlate better than HVR at SL to PASP at HA. In 20 participants at SL, 
we measured normobaric, isocapnic HVR (L/min·-%SpO2-1) and resting PASP using echocardiography. 
Both resting SpO2 and PASP measures were repeated on day 2 (n=10), days 4-8 (n=12), and 2-3 weeks 
(n=8) after arrival at 5050m. These data were also collected at 5050m on life-long HA residents (Sherpa; 
n=21). Compared to SL, SpO2 decreased from 98.6 to 80.5% (P<0.001), while PASP increased from 
21.7 to 34.0mmHg (P<0.001) after 2-3 weeks at 5050m. Isocapnic HVR at SL was not related to SpO2 
or PASP at any time point at 5050m (all P>0.05). Sherpa had lower PASP (P<0.01) than lowlanders on 
days 4-8 despite similar SpO2. Upon correction for hematocrit, Sherpa PASP was not different from 
lowlanders at SL, but lower than lowlanders at all HA time points. At 5050m, whilst SpO2 was not 
related to PASP in lowlanders at any point (all R2=<0.05; P>0.50), there was a weak relationship in the 
Sherpa (R2=0.16; P=0.07). We conclude that neither HVR at SL nor resting SpO2 at HA correlates with 
elevations in PASP at HA. 
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Introduction: 
The initial increase in ventilation in response to hypoxia (i.e. hypoxic ventilatory response; HVR) is 
highly variable1. In response to a decreased partial pressure of oxygen (PO2) at high altitude (HA), 
pulmonary artery pressure (PAP) increases primarily through hypoxic pulmonary vasoconstriction 
(HPV)2.  In some studies, a blunted HVR is characteristic of high altitude pulmonary edema (HAPE) 
susceptible subjects who exhibit marked elevations in PAP3–9. The latter findings highlight a link 
between HVR and PAP at altitude. 
Animal studies have clearly demonstrated that higher peripheral chemoreceptor responsiveness 
attenuates HPV10,11. For example, following mechanical ventilation of the lungs with 100% N2, 
stimulation of the carotid chemoreceptors via arterial hypoxemia reduces pulmonary vascular resistance 
in cats and dogs12,13. This neural modulation of PAP in hypoxia has been studied recently in humans by 
interpolating the pulmonary artery systolic pressure (PASP) response to hypoxia at a specific peripheral 
oxyhemoglobin saturation (SpO2=85%).14 Between-individual variability in HVR (indicative of 
peripheral chemoreceptor responsiveness) at SL was moderately correlated (R2=0.38) with PASP in 
normobaric hypoxia.14 This finding is consistent with the aforementioned reports linking HVR to HAPE 
susceptibility, and HAPE to excessive HPV. Furthermore, individuals with a blunted HVR will 
consequently have a lower alveolar PO2 and thus a greater stimulus to HPV at any given altitude14. 
However, the issue with extrapolating variability in HVR at SL to predict changes in PAP at HA is that, 
in addition to acid-base adjustments, HVR represents a reflex arc with three components: (1) afferent 
input, (2) central integration, and (3) efferent output15, all of which are likely changing, resulting in an 
overall change in HVR at HA16,17. Due to the myriad of physiologic changes at HA related to the 
HVR18–20 and HPV21, we hypothesized that resting SpO2 at HA would correlate better than variability in 
HVR at SL to PASP at HA (i.e., by virtue of SpO2 reflecting alveolar PO2 and hence HPV).  We also 
reasoned that chronic adaptation to HA, as seen in the Sherpa, would result in higher resting SpO2 and 
lower PASP than that of lowlanders at HA. 
	   5	  
Methods 
Study Participants and Design 
All experimental procedures and protocols were approved by the Clinical Research Ethics Board at the 
University of British Columbia, University of Otago, and the Nepal Health Medical Research Council, 
and conformed to the Declaration of Helsinki. Twenty Caucasian lowlanders (34±7 years, 5 females) 
and twenty-one Nepalese male highland Sherpa (31±13 years) provided informed consent and 
volunteered to participate in the study. One to two months prior to departure, Caucasian participants 
underwent a transthoracic echocardiographic assessment at or close to SL (see below), and then again at 
day two (n=10; from 2008), 4-8 days (5.2±0.8; further referred to as day five; n=12; 10 from 2008, two 
from 2012), and between 2 to 3 weeks (16±0.7 days; n=8; from 2012) after arrival at the Ev-K2-CNR 
Pyramid Research Laboratory (Lobuche, Nepal; 5050m) in the absence of acute mountain sickness 
(AMS) symptoms. Sherpa were assessed at 5050m only. All participants were free from respiratory and 
cardiovascular disease and were not taking any prescription medications. The native Sherpa participants 
originated from, and were residents of, the Khumbu Valley at an altitude greater than 3000m and self-
identified to be of Sherpa ethnicity. None of the Sherpa had travelled below 2800m for at least 6 months 
prior to testing. Height, body mass, blood pressure, and SpO2 were recorded prior to each transthoracic 
echocardiographic assessment (see below “Transthoracic Echocardiography”). Peripheral and central 
chemoreflex sensitivities were also assessed on a different day at SL (see below “Chemoreflex testing”).  
Prior to each experiment, participants abstained from exercise and alcohol for 24h, and caffeine for 12h. 
 
In different participants, SL data were collected in February 2008 (n=10) in Dunedin (New Zealand; at 
~10m) and in April 2012 (n=10) in Kelowna (Canada; altitude 344m). The HA experiments were 
completed over 2 weeks (2008) and 3 weeks (2012) at the Ev-K2-CNR Pyramid Laboratory, Khumbu 
region, Nepal in April-May of 2008 (New Zealand group) and 2012 (Canada group). After travel to 
Nepal and seven nights in Kathmandu (~1400m), participants flew to Lukla (2800m) and began an 8-11 
day ascent to the Pyramid Research Laboratory (5050m). A cautious ascent profile was adopted, with 
≤700m net gain per day and at least two days with no net change in altitude. Participants were given 
low-dose acetazolamide (125mg, oral) twice per day as an acute mountain sickness prophylactic22. 
Acetazolamide was discontinued at ~4300m (Pheriche), at least one day before ascending to the 
laboratory, to allow sufficient time (e.g., ≥48 hours) for the drug to clear participants’ system prior to the 
first data collection session at 5050m23,24. Previously, pre-treatment of acetazolamide has resulted in an 
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almost negligible difference of PASP (~2mmHg; no statistical analyses were performed) 48hours after 
final drug treatment when compared to individuals that received placebo treatment25. Although unlikely 
to alter our findings, we were unable to rule out the possibility of persisting physiological sequelae 
secondary to acetazolamide treatment during our day two testing. Participants spent 1 to 3 days at 
Pheriche before the final ascent. Expedition members participating in this study had a minimum of 48h 
between this and other studies involving pharmaceutical interventions or exercise, to minimize 
contamination. Some of the data presented here (e.g., chemosensitivity responses, pulmonary pressures) 
have been reported previously in other studies from these expeditions26–29; however, the research 
question addressed here is distinct, and combining data from these two expeditions provides a novel data 
set, with greater power to address the research question30.  
 
Transthoracic Echocardiography 
All echocardiographic images were recorded on a commercially available portable ultrasound system 
(Vivid I, GE Healthcare, Australia-2008 & Vivid Q, GE Medical Systems, Israel Ltd-2012). Images 
were captured by the same highly trained cardiac sonographer within each expedition (Yeoman, D.J., 
2008 & Stembridge, M., 2012) while the participant lay in the left lateral decubitus position. Following 
10 minutes of supine rest, an apical four chamber view was visualized for the recording of the systolic 
tricuspid regurgitation jet velocity (TRV) using continuous wave Doppler with the atrio-ventricular 
pressure gradient calculated using the simplified Bernoulli equation (4TRV2). PASP was then calculated 
with the addition of right atrial pressure estimated from the collapsibility of the inferior vena cava on 
inspiration31. Heart rate was recorded via 3-lead electrocardiogram. 
Chemoreflex testing 
The respiratory chemoreflex responses to both hypoxia (an index of peripheral chemoreflex sensitivity; 
HVR) and hypercapnia (an index of central chemoreflex sensitivity; HCVR) were assessed at SL in the 
2008 and 2012 studies; however, these tests differed slightly between investigations. Specifically, in the 
2008 experiments, isocapnic hypoxia was induced for approximately 4-9 minutes via a 6-L rebreathing 
bag and soda lime reservoir. The isocapnic hypoxia was terminated when either: 1) partial pressure of 
end-tidal oxygen (PETO2) reached 45mmHg at SL; 2) ventilation (V̇E) exceeded 100L/min; or 3) the 
participant reached the end of their tolerance. In the 2012 experiments, isocapnic hypoxia (PETO2 = 
47mmHg) was maintained over 10 minutes via end-tidal forcing, as described in depth elsewhere29,32. 
Despite the different methods, in a sub-group of participants (n=6) who underwent both tests, the peak 
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HVR between tests was comparable (R2=0.46; P<0.05) and not significantly different from one another 
(P=0.6), indicating they both reflected similar chemoreflex phenomena. In 2012, a subgroup (n=8) of 
participants at SL underwent 10 minutes of poikilocapnic hypoxia (11% O2) to simulate 5050m. 
Although acute poikilocapnic hypoxia testing is more complicated than the commonly used isocapnic 
hypoxic tests, due to the interactive effects of hypoxia and concomitant hypocapnia, they are more 
representative of the uncontrolled breathing environment at HA, and therefore, more applicable to such 
scenarios.  
 
In 2008, HCVR was assessed from a 4-min steady state hyperoxic hypercapnia gas mixture (7% CO2; 
93% O2) after a 5-min room air baseline. In 2012, HCVR was assessed using end-tidal forcing where 
the partial pressure of end-tidal carbon dioxide (PETCO2) was clamped initially at baseline and then 
elevated in a stepwise fashion at +5, +10, and +15mmHg from individual baseline values while PETO2 
was maintained at individual baseline values (~100mmHg).  In a sub-group of participants (n=7) who 
underwent both tests, the relationship (R2) between HCVR tests was 0.53 (P<0.01). 
 
In both the 2008 and 2012 experiments, all respiratory parameters were acquired at 200Hz using an 
analog-to-digital converter (PowerLab/16SP ML 880; ADInstruments, Colorado Springs, CO, USA) 
interfaced with a personal computer and analyzed with commercially available software (LabChart, 
ADInstruments). Throughout all procedures, participants breathed through a mouthpiece (with nose-
clip) or facemask with an attached bacteriological filter, and a two-way non-rebreathing valve (2600 
series, Hans Rudolph, Shawnee, KS, USA). Respired gas was sampled at the mouth and analyzed for 
PETO2 and PETCO2 by a calibrated gas analyzer (ML206; ADInstruments).  Respiratory flow was 
measured near the mouth using a pneumotachograph (HR 800L, HansRudolph) and a differential 
pressure amplifier (ML141, ADInstruments). 
 
Calculations 
For the 2008 studies, isocapnic HVR was calculated as the slope of the linear regression between V̇E 
and SpO2, while HCVR was calculated as ΔV̇E/ΔPETCO2 from baseline to steady state. For the 2012 
studies, isocapnic HVR was calculated as ΔV̇E/ΔSpO2 from baseline to the peak ventilation during 
hypoxia. Peak poikilocapnic HVR was calculated in a similar manner, while delayed poikilocapnic 
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HVR was calculated as ΔV̇E/ΔSpO2 from baseline to the average of minutes 10-15 of hypoxia. The 
HCVR was calculated as the linear regression slope between V̇E and PETCO2.  
 
To account for differences in hematocrit (HCT) between groups we estimated PASP after correction of 
HCT to sea level values (45%). First, we calculated pulmonary vascular resistance (PVR) in all of our 
subjects using the following equation31: 
 
PVR = TRV/RVOT VTI · 10 + 0.16 
 
Where TRV is tricuspid regurgitation velocity (m/s), and RVOT VTI is the right ventricular outflow 
tract velocity time integral (cm), and PVR is pulmonary vascular resistance expressed in woods units. 
Once this was determined for both lowlanders and Sherpa at high altitude, we calculated PVR at a HCT 
of 45% in all individuals using the following equation33: 
 
PVR(45%) = PVR(HCT%)  !!  !!/!!.!"#  
 
Where ϕ represents the hematocrit at HA. As pressure is proportional to resistance, we infer the 
calculated %change in PVR to be representative of the %change effect of hematocrit on PASP, and as 
such adjusted PASP values to a 45%HCT estimate in all groups. For the day two group we used a HCT 
value of 45.7%27, while day five, 2-3 weeks, and Sherpa HCT were 49.4%27, 49.4%29, and 53.9%29, 
respectively. 
 
Statistical Analyses 
Comparison of lowlanders at SL, day two, day five, and 2-3 weeks at altitude, as well as Sherpa were 
performed using a 1-factor ANOVA. The relationship between variables (SpO2, HVR, HCVR, & PASP) 
was assessed using least squares linear regression following conformation of a Gaussian distribution. 
Alpha was set a priori to 0.05. All statistical analyses were performed using Prism (Version 5.0b, 2008) 
and SPSS (IBM Statistics, Version 21, 2012). 
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Results 
Baseline Characteristics 
Consistent with previous reports of HVR and HCVR at 4300m34,35, we found no significant sex 
differences for chemoreflexes at sea level and both PASP and SpO2 at HA; therefore, data for males and 
females were pooled for statistical analysis. At HA, SpO2 decreased from its SL value of 98.6±1.1% to 
79.5±2.9% (P<0.001) on day two, 83.4±1.9% (P<0.001) on day five, and 80.5±1.6% (P<0.001) after 2-3 
weeks acclimatization at 5050m; at these time points, PASP increased from 21.7±2.1mmHg at SL to 
36.6±4.6mmHg (P<0.001), 35.7±5.5mmHg (P<0.001), and 34.0±4.5mmHg (P<0.001), respectively. 
Isocapnic HVR at SL was 1.61±0.94 (L/min · -SpO2-1), while peak and delayed poikilocapnic HVR 
were 0.46±0.23 and 0.14±0.08 (L/min · -SpO2-1), respectively. HCVR at SL was 3.00±1.49 (L/min · 
mmHg PETCO2-1). Correction of lowlander PASP to a HCT of 45% indicated that independent of blood 
viscosity PASP still significantly increased from 21.7±2.1mmHg at sea level to 35.9±4.5mmHg 
(P<0.001) on day two, 31.9±5.0mmHg (P<0.001) on day five, and 30.4±41mmHg (P<0.01) after 2-
3weeks acclimatization. 
 
Relationship between chemoreflexes and PASP at HA 
Elevations in PASP at 5050m after 2-3 weeks acclimatization were unrelated to SL isocapnic HVR 
(R2<0.01; P=0.97; Figure 1), SL peak poikilocapnic HVR (R2=0.16; P=0.38), and SL delayed 
poikilocapnic HVR (R2=0.13; P=0.42). Variability in the HCVR was also unrelated to the changes in 
PASP (R2=0.08; P=0.50). Poikilocapnic HVR (peak & delayed) and isocapnic HVR (see Figure 1) were 
unrelated to SpO2 after 2-3 weeks acclimatization. These relationships remained insignificant when 
ventilatory tests were related to PASP and SpO2 values on day two and day five at 5050m. Furthermore, 
incorporating individual variability at SL and HA via calculation of delta scores (i.e., HA-SL) did not 
render any significant relationships.  
 
Sherpa had higher SpO2 (82.8±3.3 vs. 79.5±2.9%; P<0.01) but lower PASP (29.8±5.9 vs. 
36.6±4.6mmHg; P<0.01) compared to lowlanders on day two at 5050m. However, on day five, although 
Sherpa had comparable SpO2 (82.8±3.3 vs. 83.4±1.9%; P=0.56), PASP was still lower compared with 
lowlanders (29.8±5.9 vs. 35.65±5.5mmHg; P<0.01). After 2-3 weeks acclimatization, Sherpa and 
lowlander SpO2 were not different (82.8±3.3 vs. 80.5±1.6%; P=0.07); however, PASP still tended to be 
lower in the Sherpa (29.8±5.9 vs. 34.0±4.5mmHg; P=0.06). Upon correction for HCT to 45% Sherpa 
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PASP was reduced to 23.7±4.7mmHg, which was not different from lowlanders at sea level (P=0.09), 
but significantly lower than lowlanders at all HA time points (all P<0.01). Regression analysis revealed 
similar non-significant correlations between HA SpO2 and PASP in lowlanders on day two at altitude 
(R2=0.03; P=0.61), day five (R2=0.05; P=0.51), and after 2-3weeks acclimatization (R2=0.03; P=0.69), 
and in Sherpa (R2=0.16; P=0.07). On examination of the group regressions, the slopes for lowlanders on 
day two, day five, after 2-3 weeks acclimatization and Sherpa were -0.29, 0.67, -0.49 and -0.74mmHg · 
-%SpO2-1, respectively (Figure 2).  
 
Discussion 
The primary finding of this study is the lack of correlation between both peripheral and central 
chemosensitivity at SL and PASP at HA, contrary to previous findings during SL hypoxia.14 
Furthermore, at any time point, there was no relationship between HA SpO2 and resting PASP at 5050m 
in SL dwellers. Consistent with our second hypothesis, Sherpa had higher SpO2 and lower PASP than 
lowlanders on day two at HA.  Early acclimatization eliminated the difference in SpO2 between Sherpa 
and lowlanders while PASP was generally lower in the native highlanders. 
 
Changes in peripheral chemoreceptor responsiveness19,36,37, central processing 18,20,38, and the 
consequent efferent output18 all effect the ventilatory response to hypoxia at altitude16,17.  The further 
effect of changes in acid-base balance, as well as the complex nature of breathing at HA have been 
reviewed in detail15. Therefore, although SL HVR has been correlated with PASP during normobaric 
hypoxia (SpO2=85%; n=15)14, the lack of correlation (of both isocapnic and poikilocapnic HVR) to 
PASP at HA is perhaps not surprising due to the aforementioned changes, in addition to changes in lung 
diffusion capacity39, which occur upon exposure to altitude.  Moreover, as HVR rapidly increases within 
the first week of exposure to HA16,17, and full ventilatory acclimatization may take up to 4-6 weeks at 
5050m15, it is further not surprising that SL HVR was unrelated to PASP at all HA time points. 
Although a blunted HVR has been reported in some studies to related to HAPE susceptibility40,41, we did 
not include any AMS/HAPE susceptible subjects by design and ensured safe ascent and acclimatization. 
As most studies derive their relationships via the use of two distinct phenotypes (i.e. AMS susceptible 
and non-susceptible who often have a blunted and brisk HVR40–43, respectively), having a singular 
phenotype within our participant group may preclude any relationship between HVR and PASP.  
However, this does not undermine the significance that biological variability in SL HVR does not 
predict the marked variability in PASP at HA in a homogenous group. 
 
An inverse relationship between SpO2 and PAP was reported as early as 1957 at 4540m44.  As a 
reduction in alveolar PO2 is the primary stimulus for HPV2,45, we reasoned that SpO2 at HA would 
correlate more strongly to PASP than SL HVR.  However, we acknowledge that the regulation of 
elevations in PAP upon exposure to HA involves the complex interaction of multiple factors and hence, 
likely explains the unremarkable correlation found between SpO2 and PASP in lowlanders and Sherpa.  
This is evidenced by incomplete restoration of normal PAP in lowlanders3,46 and Sherpa29 upon 
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alleviation of alveolar hypoxia.   Our findings are consistent with earlier reports that Sherpa have higher 
resting SpO2 than lowlanders upon initial arrival to high altitudes (i.e., >4000m; day two in this 
investigation). Similar SpO2 between Sherpa and lowlanders after 1-3 weeks acclimatization is likely 
due to progressive ventilatory acclimatization and consequent elevations in resting ventilation. Previous 
studies have reported a significant47 and trending48 inverse relationship between SpO2 and PAP; 
however, this is not a consistent finding28,44.  Furthermore, PASP has been reported as both lower48 and 
the same28,29 in Sherpa than lowlanders at HA, with the differing results likely due to duration of time at 
altitude prior to assessment29 and small sample sizes. Our data, which includes a larger sample size of 
Sherpa than previous investigations, showed that despite similar SpO2 to lowlanders after ~5 days 
acclimatization, Sherpa continued to have lower PASP. Therefore, several other key factors that act to 
regulate PAP at HA in addition to alveolar PO2 2,45 must be interacting in a different manner between 
Sherpa and lowlander populations.  These factors likely include pulmonary vascular remodeling to life 
at HA49, genetic adaptations, higher circulating nitric oxide in Sherpa as compared to lowlanders50, and 
blood viscosity29. To provide insight into this latter point, we corrected both lowlander and Sherpa 
PASP values to a sea level HCT (45%). After correction, PASP in Sherpa fell within sea level norms at 
~24mmHg therefore indicating that hematocrit and subsequently viscosity are predominantly 
responsible for their elevated PASP at 5050m. This further provides evidence suggesting a differential 
regulation of PASP between lowlanders and high altitude natives, and indicates that we and others28,29,48 
have likely underestimated the difference in HPV between lowlanders and Sherpa without consideration 
of changes in HCT33.  
 
In conclusion, as the multiple factors regulating breathing differ between SL and HA, the utility of SL 
chemoreflex tests, both poikilocapnic and isocapnic, to predict changes in PASP at HA is limited in 
otherwise healthy individuals.  
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Figures: 
 
 
  
Figure 1. The relationship between sea level isocapnic HVR and both SpO2 (A) and PASP (B) in 
lowlanders within day two (closed circles, solid line), day five (open circles, dashed line) and after 2-3 
weeks acclimatization (filled squares, dashed line). HVR was unrelated to SpO2 on day two (R2=0.24; 
P=0.14), day five (R2=0.12; P=0.27) and after 2-3weeks acclimatization (R2=0.10; P=0.46). The 
relationship between sea level isocapnic HVR with PASP at high altitude on day two (R2=0.03; P=0.64), 
day five (R2=0.25; P=0.12), and after 2-3 weeks acclimatization (R2<0.01; P =0.97) were also 
insignificant. HVR, hypoxic ventilatory response; PASP, pulmonary artery systolic pressure; SpO2, 
peripheral oxyhemoglobin saturation. 
 
 
Figure 2. The influence of peripheral oxyhemoglobin saturation (SpO2) on PASP at high altitude in 
lowlanders on day two (closed circles, thin solid line), day five (open circles, dashed line), after 2-3 
weeks altitude (filled squares, thick solid line), as well as in Sherpa (open squares, dotted line).  
Regression analysis revealed non-significant correlations between high altitude SpO2 and PASP on day 
two (R2=0.03; P=0.61), day five (R2=0.05; P=0.51), and after 2-3weeks acclimatization (R2=0.03; 
P=0.69), and in Sherpa (R2=0.16; P=0.07). PASP, pulmonary artery systolic pressure; HA, high altitude; 
SpO2, peripheral oxyhemoglobin saturation. 
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